Date: 2025/06/11 - 18:32
Calorie-restricted dieting is linked to an increased risk of depression in a new study that finds anyone who is on a "diet" is more likely to be depressed. The findings were especially pronounced in people with overweight.
Date: 2025/05/19 - 22:32
Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly. Participants who received tirzepatide also had greater improvements in metabolic risk factors. Tirzepatide's dual effects on GLP-1 and GIP may explain its superior performance.
Date: 2025/05/18 - 16:31
Semaglutide, available under the brand names Ozempic and Wegovy, may help decrease the risk of major adverse cardiovascular events after just six months of starting the medication, a new study indicates.
Date: 2025/05/15 - 19:00
Three months of 8-hour time-restricted eating (TRE), regardless of the time of the day, helped sustain long-term weight loss in adults with overweight or obesity, preliminary results from a clinical trial has shown.
Date: 2025/05/13 - 23:32
First-generation GLP-1 weight-loss drugs can help reduce the risk of obesity-related cancers, new research shows. Liraglutide, exenatide, and dulaglutide were 41% more effective at preventing obesity-related cancers.